Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7978MR)

This product GTTS-WQ7978MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7978MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6170MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ4020MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ8266MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ8461MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ1063MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ12855MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ7958MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ2108MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW